154 results on '"Niu, Wenbin"'
Search Results
152. Chromatin analysis in human early development reveals epigenetic transition during ZGA.
- Author
-
Wu J, Xu J, Liu B, Yao G, Wang P, Lin Z, Huang B, Wang X, Li T, Shi S, Zhang N, Duan F, Ming J, Zhang X, Niu W, Song W, Jin H, Guo Y, Dai S, Hu L, Fang L, Wang Q, Li Y, Li W, Na J, Xie W, and Sun Y
- Subjects
- Animals, Binding Sites, CpG Islands genetics, DNA Methylation, Embryo, Mammalian cytology, Embryo, Mammalian embryology, Embryonic Stem Cells cytology, Female, Gene Silencing, High-Throughput Nucleotide Sequencing, Humans, Male, Mice, Oocytes cytology, Oocytes metabolism, Pluripotent Stem Cells cytology, Promoter Regions, Genetic genetics, Transcription Factors metabolism, Transposases metabolism, Chromatin genetics, Chromatin metabolism, Embryo, Mammalian metabolism, Embryonic Development genetics, Epigenesis, Genetic, Genome genetics, Zygote metabolism
- Abstract
Upon fertilization, drastic chromatin reorganization occurs during preimplantation development
1 . However, the global chromatin landscape and its molecular dynamics in this period remain largely unexplored in humans. Here we investigate chromatin states in human preimplantation development using an improved assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq)2 . We find widespread accessible chromatin regions in early human embryos that overlap extensively with putative cis-regulatory sequences and transposable elements. Integrative analyses show both conservation and divergence in regulatory circuitry between human and mouse early development, and between human pluripotency in vivo and human embryonic stem cells. In addition, we find widespread open chromatin regions before zygotic genome activation (ZGA). The accessible chromatin loci are readily found at CpG-rich promoters. Unexpectedly, many others reside in distal regions that overlap with DNA hypomethylated domains in human oocytes and are enriched for transcription factor-binding sites. A large portion of these regions then become inaccessible after ZGA in a transcription-dependent manner. Notably, such extensive chromatin reorganization during ZGA is conserved in mice and correlates with the reprogramming of the non-canonical histone mark H3K4me3, which is uniquely linked to genome silencing3-5 . Taken together, these data not only reveal a conserved principle that underlies the chromatin transition during mammalian ZGA, but also help to advance our understanding of epigenetic reprogramming during human early development and in vitro fertilization.- Published
- 2018
- Full Text
- View/download PDF
153. Mapping allele with resolved carrier status of Robertsonian and reciprocal translocation in human preimplantation embryos.
- Author
-
Xu J, Zhang Z, Niu W, Yang Q, Yao G, Shi S, Jin H, Song W, Chen L, Zhang X, Guo Y, Su Y, Hu L, Zhai J, Zhang Y, Dong F, Gao Y, Li W, Bo S, Hu M, Ren J, Huang L, Lu S, Xie XS, and Sun Y
- Subjects
- Alleles, Chromosome Aberrations, Embryo Transfer, Female, Humans, Infertility genetics, Live Birth, Male, Pregnancy, Pregnancy Outcome, Blastocyst, Fertilization in Vitro, Genetic Carrier Screening methods, Infertility therapy, Preimplantation Diagnosis, Translocation, Genetic
- Abstract
Reciprocal translocations (RecT) and Robertsonian translocations (RobT) are among the most common chromosomal abnormalities that cause infertility and birth defects. Preimplantation genetic testing for aneuploidy using comprehensive chromosome screening for in vitro fertilization enables embryo selection with balanced chromosomal ploidy; however, it is normally unable to determine whether an embryo is a translocation carrier. Here we report a method named "Mapping Allele with Resolved Carrier Status" (MaReCs), which enables chromosomal ploidy screening and resolution of the translocation carrier status of the same embryo. We performed MaReCs on 108 embryos, of which 96 were from 13 RecT carriers and 12 were from three RobT carriers. Thirteen of the sixteen patients had at least one diploid embryo. We have confirmed the accuracy of our carrier status determination in amniotic fluid karyotyping of seven cases as well as in the live birth we have thus far. Therefore, MaReCs accurately enables the selection of translocation-free embryos from patients carrying chromosomal translocations. We expect MaReCs will help reduce the propagation of RecT/RobT in the human population., Competing Interests: Conflict of interest statement: S.L. and X.S.X. are cofounders and shareholders of Yikon Genomics Company, Ltd. Z.Z., Y. Gao, W.L., S.B., M.H., and J.R. receive research funding from Yikon Genomics Company, Ltd.
- Published
- 2017
- Full Text
- View/download PDF
154. Dehydroepiandrosterone treatment in women with poor ovarian response undergoing IVF or ICSI: a systematic review and meta-analysis.
- Author
-
Zhang M, Niu W, Wang Y, Xu J, Bao X, Wang L, Du L, and Sun Y
- Subjects
- Abortion, Spontaneous, Endometrium physiology, Female, Humans, Pregnancy, Pregnancy Outcome, Dehydroepiandrosterone therapeutic use, Ovarian Reserve drug effects, Ovulation Induction methods, Sperm Injections, Intracytoplasmic methods
- Abstract
Purpose: We reviewed the influence of dehydroepiandrosterone (DHEA) supplementation in patients with poor ovarian response (POR) undergoing in vitro fertilization or intracytoplasmic sperm injection (IVF/ICSI)., Methods: We searched Embase, MEDLINE, PubMed, and the Cochrane Library (1980-2015) for relevant papers and used the Newcastle-Ottawa Scale scoring system to evaluate study quality. Dichotomous data were expressed as pooled relative risk (RR) estimates with fixed or random effect models. Continuous variables were expressed as the weighted mean difference (WMD). All data were analyzed using Revman Software v. 5 and are shown with 95 % confidence intervals (CI)., Results: Twenty-one studies met the inclusion criteria. DHEA pretreatment increased the clinical pregnancy rate (RR 1.53, 95 % CI 1.25-1.86), live birth rate (RR 1.87, 95 % CI 1.22-2.88), implantation rate (RR 1.56, 95 % CI 1.20-2.01), and antral follicle count (WMD 0.4, 95 % CI 0.14 to 0.66) while reducing miscarriages (RR 0.50, 95 % CI 0.27-0.90). After subgroup analysis, oocyte numbers and anti-Müllerian hormone levels were also enhanced after DHEA treatment. However, the endometrial thickness and estradiol levels on the day of injecting hCG to induce ovulation were similar between the DHEA supplementation groups and controls., Conclusions: Based on the limited available evidence, DHEA supplementation seems to improve ovarian reserves and IVF/ICSI outcome in patients with POR. Further research is required to clarify the effect of DHEA exposure in assisted reproduction technology.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.